2 results
Approved WMOCompleted
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Approved WMOCompleted
The aim of this study is to determine NET availability in patients with neurodegenerative diseases to characterize NA system degeneration in people with Alzheimer's disease, Parkinson's disease (with and without dementia) and with…